Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
Asthma
What is your preferred rescue inhaler for patients with asthma?
Do you favor albuterol PRN, albuterol/budesonide PRN, or SMART therapy with ICS/formoterol?
Answer from: at Community Practice
The problem with using ICS/formoterol is that the patient will run out of doses before the end of the month if they take it on a BID basis.
Sign in or Register to read more
Answer from: at Academic Institution
SMART with ICS/formoterol. I tend to think all asthma patients should be on SMART therapy (ICS/formoterol). Just don't really see the reason to not treat that way.
Sign in or Register to read more
26869
27010
Related Questions
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
Would you stop Dupixent in an asthma patient who has good asthma control and notes improvement in loss of smell, but shows notable eosinophil elevation after 4-5 doses of the medication?
Have you observed adverse mental health side effects in patients who start montelukast?
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
When do you consider switching from another biologic to benralizumab in patients with severe eosinophilic asthma with a history of suboptimal response to previous biologic agents?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
How might the introduction of brensocatib as a treatment option impact the use of other anti- inflammatory or antibiotic therapies currently employed in bronchiectasis management?
Should a patient on medium-dose ICS/LABA with normal PFTs, but who shows a greater than 10% decrease in FEV1 if their PFTs are done after 24 hours off their inhaler, be started on a biologic?